Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: Illustration with the case of taxane therapeutics
This review is aimed at combining the published data on taxane formulations into a generalized Drug Delivery approach, starting from the physicochemistry and assessing its relationships with the pharmacokinetics, the biodistribution and the pharmacodynamics. Owing to the number and variety of taxane...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Reddy, L. Harivardhan [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2014transfer abstract |
|---|
| Umfang: |
24 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Parents’ ambitions and children’s competitiveness - Khadjavi, Menusch ELSEVIER, 2018, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:71 ; year:2014 ; pages:34-57 ; extent:24 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.addr.2013.10.007 |
|---|
| Katalog-ID: |
ELV022495916 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV022495916 | ||
| 003 | DE-627 | ||
| 005 | 20230625135541.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.addr.2013.10.007 |2 doi | |
| 028 | 5 | 2 | |a GBVA2014006000010.pica |
| 035 | |a (DE-627)ELV022495916 | ||
| 035 | |a (ELSEVIER)S0169-409X(13)00249-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 150 |a 300 |a 330 |q VZ |
| 084 | |a 77.00 |2 bkl | ||
| 100 | 1 | |a Reddy, L. Harivardhan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: Illustration with the case of taxane therapeutics |
| 264 | 1 | |c 2014transfer abstract | |
| 300 | |a 24 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a This review is aimed at combining the published data on taxane formulations into a generalized Drug Delivery approach, starting from the physicochemistry and assessing its relationships with the pharmacokinetics, the biodistribution and the pharmacodynamics. Owing to the number and variety of taxane formulation designs, we considered this class of cytotoxic anticancer agents of particular interest to illustrate the concepts attached to this approach. According to the history of taxane development, we propose a classification as (i) “surfactant-based formulations” first generation, (ii) “surfactant-free formulations” second generation and (iii) “modulated pharmacokinetics drug delivery systems” third generation. Since our objective was to make the link between (i) the physicochemistry of the drug and carrier and (ii) the efficacy and safety of the drug in preclinical animal models and (iii) in human, we focused on the drug delivery technologies that were tested in clinic. | ||
| 520 | |a This review is aimed at combining the published data on taxane formulations into a generalized Drug Delivery approach, starting from the physicochemistry and assessing its relationships with the pharmacokinetics, the biodistribution and the pharmacodynamics. Owing to the number and variety of taxane formulation designs, we considered this class of cytotoxic anticancer agents of particular interest to illustrate the concepts attached to this approach. According to the history of taxane development, we propose a classification as (i) “surfactant-based formulations” first generation, (ii) “surfactant-free formulations” second generation and (iii) “modulated pharmacokinetics drug delivery systems” third generation. Since our objective was to make the link between (i) the physicochemistry of the drug and carrier and (ii) the efficacy and safety of the drug in preclinical animal models and (iii) in human, we focused on the drug delivery technologies that were tested in clinic. | ||
| 700 | 1 | |a Bazile, Didier |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Khadjavi, Menusch ELSEVIER |t Parents’ ambitions and children’s competitiveness |d 2018 |g Amsterdam [u.a.] |w (DE-627)ELV000099058 |
| 773 | 1 | 8 | |g volume:71 |g year:2014 |g pages:34-57 |g extent:24 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.addr.2013.10.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 77.00 |j Psychologie: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 71 |j 2014 |h 34-57 |g 24 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
l h r lh lhr |
|---|---|
| matchkey_str |
reddylharivardhanbaziledidier:2014----:rgeieyeinoitaeosotwtitgaepyiohmsrpamckntcadhraoyaislut |
| hierarchy_sort_str |
2014transfer abstract |
| bklnumber |
77.00 |
| publishDate |
2014 |
| allfields |
10.1016/j.addr.2013.10.007 doi GBVA2014006000010.pica (DE-627)ELV022495916 (ELSEVIER)S0169-409X(13)00249-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 150 300 330 VZ 77.00 bkl Reddy, L. Harivardhan verfasserin aut Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: Illustration with the case of taxane therapeutics 2014transfer abstract 24 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier This review is aimed at combining the published data on taxane formulations into a generalized Drug Delivery approach, starting from the physicochemistry and assessing its relationships with the pharmacokinetics, the biodistribution and the pharmacodynamics. Owing to the number and variety of taxane formulation designs, we considered this class of cytotoxic anticancer agents of particular interest to illustrate the concepts attached to this approach. According to the history of taxane development, we propose a classification as (i) “surfactant-based formulations” first generation, (ii) “surfactant-free formulations” second generation and (iii) “modulated pharmacokinetics drug delivery systems” third generation. Since our objective was to make the link between (i) the physicochemistry of the drug and carrier and (ii) the efficacy and safety of the drug in preclinical animal models and (iii) in human, we focused on the drug delivery technologies that were tested in clinic. This review is aimed at combining the published data on taxane formulations into a generalized Drug Delivery approach, starting from the physicochemistry and assessing its relationships with the pharmacokinetics, the biodistribution and the pharmacodynamics. Owing to the number and variety of taxane formulation designs, we considered this class of cytotoxic anticancer agents of particular interest to illustrate the concepts attached to this approach. According to the history of taxane development, we propose a classification as (i) “surfactant-based formulations” first generation, (ii) “surfactant-free formulations” second generation and (iii) “modulated pharmacokinetics drug delivery systems” third generation. Since our objective was to make the link between (i) the physicochemistry of the drug and carrier and (ii) the efficacy and safety of the drug in preclinical animal models and (iii) in human, we focused on the drug delivery technologies that were tested in clinic. Bazile, Didier oth Enthalten in Elsevier Science Khadjavi, Menusch ELSEVIER Parents’ ambitions and children’s competitiveness 2018 Amsterdam [u.a.] (DE-627)ELV000099058 volume:71 year:2014 pages:34-57 extent:24 https://doi.org/10.1016/j.addr.2013.10.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.00 Psychologie: Allgemeines VZ AR 71 2014 34-57 24 045F 610 |
| spelling |
10.1016/j.addr.2013.10.007 doi GBVA2014006000010.pica (DE-627)ELV022495916 (ELSEVIER)S0169-409X(13)00249-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 150 300 330 VZ 77.00 bkl Reddy, L. Harivardhan verfasserin aut Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: Illustration with the case of taxane therapeutics 2014transfer abstract 24 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier This review is aimed at combining the published data on taxane formulations into a generalized Drug Delivery approach, starting from the physicochemistry and assessing its relationships with the pharmacokinetics, the biodistribution and the pharmacodynamics. Owing to the number and variety of taxane formulation designs, we considered this class of cytotoxic anticancer agents of particular interest to illustrate the concepts attached to this approach. According to the history of taxane development, we propose a classification as (i) “surfactant-based formulations” first generation, (ii) “surfactant-free formulations” second generation and (iii) “modulated pharmacokinetics drug delivery systems” third generation. Since our objective was to make the link between (i) the physicochemistry of the drug and carrier and (ii) the efficacy and safety of the drug in preclinical animal models and (iii) in human, we focused on the drug delivery technologies that were tested in clinic. This review is aimed at combining the published data on taxane formulations into a generalized Drug Delivery approach, starting from the physicochemistry and assessing its relationships with the pharmacokinetics, the biodistribution and the pharmacodynamics. Owing to the number and variety of taxane formulation designs, we considered this class of cytotoxic anticancer agents of particular interest to illustrate the concepts attached to this approach. According to the history of taxane development, we propose a classification as (i) “surfactant-based formulations” first generation, (ii) “surfactant-free formulations” second generation and (iii) “modulated pharmacokinetics drug delivery systems” third generation. Since our objective was to make the link between (i) the physicochemistry of the drug and carrier and (ii) the efficacy and safety of the drug in preclinical animal models and (iii) in human, we focused on the drug delivery technologies that were tested in clinic. Bazile, Didier oth Enthalten in Elsevier Science Khadjavi, Menusch ELSEVIER Parents’ ambitions and children’s competitiveness 2018 Amsterdam [u.a.] (DE-627)ELV000099058 volume:71 year:2014 pages:34-57 extent:24 https://doi.org/10.1016/j.addr.2013.10.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.00 Psychologie: Allgemeines VZ AR 71 2014 34-57 24 045F 610 |
| allfields_unstemmed |
10.1016/j.addr.2013.10.007 doi GBVA2014006000010.pica (DE-627)ELV022495916 (ELSEVIER)S0169-409X(13)00249-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 150 300 330 VZ 77.00 bkl Reddy, L. Harivardhan verfasserin aut Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: Illustration with the case of taxane therapeutics 2014transfer abstract 24 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier This review is aimed at combining the published data on taxane formulations into a generalized Drug Delivery approach, starting from the physicochemistry and assessing its relationships with the pharmacokinetics, the biodistribution and the pharmacodynamics. Owing to the number and variety of taxane formulation designs, we considered this class of cytotoxic anticancer agents of particular interest to illustrate the concepts attached to this approach. According to the history of taxane development, we propose a classification as (i) “surfactant-based formulations” first generation, (ii) “surfactant-free formulations” second generation and (iii) “modulated pharmacokinetics drug delivery systems” third generation. Since our objective was to make the link between (i) the physicochemistry of the drug and carrier and (ii) the efficacy and safety of the drug in preclinical animal models and (iii) in human, we focused on the drug delivery technologies that were tested in clinic. This review is aimed at combining the published data on taxane formulations into a generalized Drug Delivery approach, starting from the physicochemistry and assessing its relationships with the pharmacokinetics, the biodistribution and the pharmacodynamics. Owing to the number and variety of taxane formulation designs, we considered this class of cytotoxic anticancer agents of particular interest to illustrate the concepts attached to this approach. According to the history of taxane development, we propose a classification as (i) “surfactant-based formulations” first generation, (ii) “surfactant-free formulations” second generation and (iii) “modulated pharmacokinetics drug delivery systems” third generation. Since our objective was to make the link between (i) the physicochemistry of the drug and carrier and (ii) the efficacy and safety of the drug in preclinical animal models and (iii) in human, we focused on the drug delivery technologies that were tested in clinic. Bazile, Didier oth Enthalten in Elsevier Science Khadjavi, Menusch ELSEVIER Parents’ ambitions and children’s competitiveness 2018 Amsterdam [u.a.] (DE-627)ELV000099058 volume:71 year:2014 pages:34-57 extent:24 https://doi.org/10.1016/j.addr.2013.10.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.00 Psychologie: Allgemeines VZ AR 71 2014 34-57 24 045F 610 |
| allfieldsGer |
10.1016/j.addr.2013.10.007 doi GBVA2014006000010.pica (DE-627)ELV022495916 (ELSEVIER)S0169-409X(13)00249-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 150 300 330 VZ 77.00 bkl Reddy, L. Harivardhan verfasserin aut Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: Illustration with the case of taxane therapeutics 2014transfer abstract 24 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier This review is aimed at combining the published data on taxane formulations into a generalized Drug Delivery approach, starting from the physicochemistry and assessing its relationships with the pharmacokinetics, the biodistribution and the pharmacodynamics. Owing to the number and variety of taxane formulation designs, we considered this class of cytotoxic anticancer agents of particular interest to illustrate the concepts attached to this approach. According to the history of taxane development, we propose a classification as (i) “surfactant-based formulations” first generation, (ii) “surfactant-free formulations” second generation and (iii) “modulated pharmacokinetics drug delivery systems” third generation. Since our objective was to make the link between (i) the physicochemistry of the drug and carrier and (ii) the efficacy and safety of the drug in preclinical animal models and (iii) in human, we focused on the drug delivery technologies that were tested in clinic. This review is aimed at combining the published data on taxane formulations into a generalized Drug Delivery approach, starting from the physicochemistry and assessing its relationships with the pharmacokinetics, the biodistribution and the pharmacodynamics. Owing to the number and variety of taxane formulation designs, we considered this class of cytotoxic anticancer agents of particular interest to illustrate the concepts attached to this approach. According to the history of taxane development, we propose a classification as (i) “surfactant-based formulations” first generation, (ii) “surfactant-free formulations” second generation and (iii) “modulated pharmacokinetics drug delivery systems” third generation. Since our objective was to make the link between (i) the physicochemistry of the drug and carrier and (ii) the efficacy and safety of the drug in preclinical animal models and (iii) in human, we focused on the drug delivery technologies that were tested in clinic. Bazile, Didier oth Enthalten in Elsevier Science Khadjavi, Menusch ELSEVIER Parents’ ambitions and children’s competitiveness 2018 Amsterdam [u.a.] (DE-627)ELV000099058 volume:71 year:2014 pages:34-57 extent:24 https://doi.org/10.1016/j.addr.2013.10.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.00 Psychologie: Allgemeines VZ AR 71 2014 34-57 24 045F 610 |
| allfieldsSound |
10.1016/j.addr.2013.10.007 doi GBVA2014006000010.pica (DE-627)ELV022495916 (ELSEVIER)S0169-409X(13)00249-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 150 300 330 VZ 77.00 bkl Reddy, L. Harivardhan verfasserin aut Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: Illustration with the case of taxane therapeutics 2014transfer abstract 24 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier This review is aimed at combining the published data on taxane formulations into a generalized Drug Delivery approach, starting from the physicochemistry and assessing its relationships with the pharmacokinetics, the biodistribution and the pharmacodynamics. Owing to the number and variety of taxane formulation designs, we considered this class of cytotoxic anticancer agents of particular interest to illustrate the concepts attached to this approach. According to the history of taxane development, we propose a classification as (i) “surfactant-based formulations” first generation, (ii) “surfactant-free formulations” second generation and (iii) “modulated pharmacokinetics drug delivery systems” third generation. Since our objective was to make the link between (i) the physicochemistry of the drug and carrier and (ii) the efficacy and safety of the drug in preclinical animal models and (iii) in human, we focused on the drug delivery technologies that were tested in clinic. This review is aimed at combining the published data on taxane formulations into a generalized Drug Delivery approach, starting from the physicochemistry and assessing its relationships with the pharmacokinetics, the biodistribution and the pharmacodynamics. Owing to the number and variety of taxane formulation designs, we considered this class of cytotoxic anticancer agents of particular interest to illustrate the concepts attached to this approach. According to the history of taxane development, we propose a classification as (i) “surfactant-based formulations” first generation, (ii) “surfactant-free formulations” second generation and (iii) “modulated pharmacokinetics drug delivery systems” third generation. Since our objective was to make the link between (i) the physicochemistry of the drug and carrier and (ii) the efficacy and safety of the drug in preclinical animal models and (iii) in human, we focused on the drug delivery technologies that were tested in clinic. Bazile, Didier oth Enthalten in Elsevier Science Khadjavi, Menusch ELSEVIER Parents’ ambitions and children’s competitiveness 2018 Amsterdam [u.a.] (DE-627)ELV000099058 volume:71 year:2014 pages:34-57 extent:24 https://doi.org/10.1016/j.addr.2013.10.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.00 Psychologie: Allgemeines VZ AR 71 2014 34-57 24 045F 610 |
| language |
English |
| source |
Enthalten in Parents’ ambitions and children’s competitiveness Amsterdam [u.a.] volume:71 year:2014 pages:34-57 extent:24 |
| sourceStr |
Enthalten in Parents’ ambitions and children’s competitiveness Amsterdam [u.a.] volume:71 year:2014 pages:34-57 extent:24 |
| format_phy_str_mv |
Article |
| bklname |
Psychologie: Allgemeines |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Parents’ ambitions and children’s competitiveness |
| authorswithroles_txt_mv |
Reddy, L. Harivardhan @@aut@@ Bazile, Didier @@oth@@ |
| publishDateDaySort_date |
2014-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000099058 |
| dewey-sort |
3610 |
| id |
ELV022495916 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV022495916</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625135541.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.addr.2013.10.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014006000010.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV022495916</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0169-409X(13)00249-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">150</subfield><subfield code="a">300</subfield><subfield code="a">330</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">77.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Reddy, L. Harivardhan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: Illustration with the case of taxane therapeutics</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">24</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This review is aimed at combining the published data on taxane formulations into a generalized Drug Delivery approach, starting from the physicochemistry and assessing its relationships with the pharmacokinetics, the biodistribution and the pharmacodynamics. Owing to the number and variety of taxane formulation designs, we considered this class of cytotoxic anticancer agents of particular interest to illustrate the concepts attached to this approach. According to the history of taxane development, we propose a classification as (i) “surfactant-based formulations” first generation, (ii) “surfactant-free formulations” second generation and (iii) “modulated pharmacokinetics drug delivery systems” third generation. Since our objective was to make the link between (i) the physicochemistry of the drug and carrier and (ii) the efficacy and safety of the drug in preclinical animal models and (iii) in human, we focused on the drug delivery technologies that were tested in clinic.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This review is aimed at combining the published data on taxane formulations into a generalized Drug Delivery approach, starting from the physicochemistry and assessing its relationships with the pharmacokinetics, the biodistribution and the pharmacodynamics. Owing to the number and variety of taxane formulation designs, we considered this class of cytotoxic anticancer agents of particular interest to illustrate the concepts attached to this approach. According to the history of taxane development, we propose a classification as (i) “surfactant-based formulations” first generation, (ii) “surfactant-free formulations” second generation and (iii) “modulated pharmacokinetics drug delivery systems” third generation. Since our objective was to make the link between (i) the physicochemistry of the drug and carrier and (ii) the efficacy and safety of the drug in preclinical animal models and (iii) in human, we focused on the drug delivery technologies that were tested in clinic.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bazile, Didier</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Khadjavi, Menusch ELSEVIER</subfield><subfield code="t">Parents’ ambitions and children’s competitiveness</subfield><subfield code="d">2018</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000099058</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:71</subfield><subfield code="g">year:2014</subfield><subfield code="g">pages:34-57</subfield><subfield code="g">extent:24</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.addr.2013.10.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">77.00</subfield><subfield code="j">Psychologie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">71</subfield><subfield code="j">2014</subfield><subfield code="h">34-57</subfield><subfield code="g">24</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Reddy, L. Harivardhan |
| spellingShingle |
Reddy, L. Harivardhan ddc 610 ddc 150 bkl 77.00 Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: Illustration with the case of taxane therapeutics |
| authorStr |
Reddy, L. Harivardhan |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000099058 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 150 - Psychology 300 - Social sciences 330 - Economics |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 150 300 330 VZ 77.00 bkl Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: Illustration with the case of taxane therapeutics |
| topic |
ddc 610 ddc 150 bkl 77.00 |
| topic_unstemmed |
ddc 610 ddc 150 bkl 77.00 |
| topic_browse |
ddc 610 ddc 150 bkl 77.00 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
d b db |
| hierarchy_parent_title |
Parents’ ambitions and children’s competitiveness |
| hierarchy_parent_id |
ELV000099058 |
| dewey-tens |
610 - Medicine & health 150 - Psychology 300 - Social sciences, sociology & anthropology 330 - Economics |
| hierarchy_top_title |
Parents’ ambitions and children’s competitiveness |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000099058 |
| title |
Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: Illustration with the case of taxane therapeutics |
| ctrlnum |
(DE-627)ELV022495916 (ELSEVIER)S0169-409X(13)00249-4 |
| title_full |
Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: Illustration with the case of taxane therapeutics |
| author_sort |
Reddy, L. Harivardhan |
| journal |
Parents’ ambitions and children’s competitiveness |
| journalStr |
Parents’ ambitions and children’s competitiveness |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 100 - Philosophy & psychology 300 - Social sciences |
| recordtype |
marc |
| publishDateSort |
2014 |
| contenttype_str_mv |
zzz |
| container_start_page |
34 |
| author_browse |
Reddy, L. Harivardhan |
| container_volume |
71 |
| physical |
24 |
| class |
610 610 DE-600 150 300 330 VZ 77.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Reddy, L. Harivardhan |
| doi_str_mv |
10.1016/j.addr.2013.10.007 |
| dewey-full |
610 150 300 330 |
| title_sort |
drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: illustration with the case of taxane therapeutics |
| title_auth |
Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: Illustration with the case of taxane therapeutics |
| abstract |
This review is aimed at combining the published data on taxane formulations into a generalized Drug Delivery approach, starting from the physicochemistry and assessing its relationships with the pharmacokinetics, the biodistribution and the pharmacodynamics. Owing to the number and variety of taxane formulation designs, we considered this class of cytotoxic anticancer agents of particular interest to illustrate the concepts attached to this approach. According to the history of taxane development, we propose a classification as (i) “surfactant-based formulations” first generation, (ii) “surfactant-free formulations” second generation and (iii) “modulated pharmacokinetics drug delivery systems” third generation. Since our objective was to make the link between (i) the physicochemistry of the drug and carrier and (ii) the efficacy and safety of the drug in preclinical animal models and (iii) in human, we focused on the drug delivery technologies that were tested in clinic. |
| abstractGer |
This review is aimed at combining the published data on taxane formulations into a generalized Drug Delivery approach, starting from the physicochemistry and assessing its relationships with the pharmacokinetics, the biodistribution and the pharmacodynamics. Owing to the number and variety of taxane formulation designs, we considered this class of cytotoxic anticancer agents of particular interest to illustrate the concepts attached to this approach. According to the history of taxane development, we propose a classification as (i) “surfactant-based formulations” first generation, (ii) “surfactant-free formulations” second generation and (iii) “modulated pharmacokinetics drug delivery systems” third generation. Since our objective was to make the link between (i) the physicochemistry of the drug and carrier and (ii) the efficacy and safety of the drug in preclinical animal models and (iii) in human, we focused on the drug delivery technologies that were tested in clinic. |
| abstract_unstemmed |
This review is aimed at combining the published data on taxane formulations into a generalized Drug Delivery approach, starting from the physicochemistry and assessing its relationships with the pharmacokinetics, the biodistribution and the pharmacodynamics. Owing to the number and variety of taxane formulation designs, we considered this class of cytotoxic anticancer agents of particular interest to illustrate the concepts attached to this approach. According to the history of taxane development, we propose a classification as (i) “surfactant-based formulations” first generation, (ii) “surfactant-free formulations” second generation and (iii) “modulated pharmacokinetics drug delivery systems” third generation. Since our objective was to make the link between (i) the physicochemistry of the drug and carrier and (ii) the efficacy and safety of the drug in preclinical animal models and (iii) in human, we focused on the drug delivery technologies that were tested in clinic. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| title_short |
Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: Illustration with the case of taxane therapeutics |
| url |
https://doi.org/10.1016/j.addr.2013.10.007 |
| remote_bool |
true |
| author2 |
Bazile, Didier |
| author2Str |
Bazile, Didier |
| ppnlink |
ELV000099058 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth |
| doi_str |
10.1016/j.addr.2013.10.007 |
| up_date |
2024-07-06T22:07:39.328Z |
| _version_ |
1803869129884565504 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV022495916</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625135541.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.addr.2013.10.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014006000010.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV022495916</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0169-409X(13)00249-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">150</subfield><subfield code="a">300</subfield><subfield code="a">330</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">77.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Reddy, L. Harivardhan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: Illustration with the case of taxane therapeutics</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">24</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This review is aimed at combining the published data on taxane formulations into a generalized Drug Delivery approach, starting from the physicochemistry and assessing its relationships with the pharmacokinetics, the biodistribution and the pharmacodynamics. Owing to the number and variety of taxane formulation designs, we considered this class of cytotoxic anticancer agents of particular interest to illustrate the concepts attached to this approach. According to the history of taxane development, we propose a classification as (i) “surfactant-based formulations” first generation, (ii) “surfactant-free formulations” second generation and (iii) “modulated pharmacokinetics drug delivery systems” third generation. Since our objective was to make the link between (i) the physicochemistry of the drug and carrier and (ii) the efficacy and safety of the drug in preclinical animal models and (iii) in human, we focused on the drug delivery technologies that were tested in clinic.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This review is aimed at combining the published data on taxane formulations into a generalized Drug Delivery approach, starting from the physicochemistry and assessing its relationships with the pharmacokinetics, the biodistribution and the pharmacodynamics. Owing to the number and variety of taxane formulation designs, we considered this class of cytotoxic anticancer agents of particular interest to illustrate the concepts attached to this approach. According to the history of taxane development, we propose a classification as (i) “surfactant-based formulations” first generation, (ii) “surfactant-free formulations” second generation and (iii) “modulated pharmacokinetics drug delivery systems” third generation. Since our objective was to make the link between (i) the physicochemistry of the drug and carrier and (ii) the efficacy and safety of the drug in preclinical animal models and (iii) in human, we focused on the drug delivery technologies that were tested in clinic.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bazile, Didier</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Khadjavi, Menusch ELSEVIER</subfield><subfield code="t">Parents’ ambitions and children’s competitiveness</subfield><subfield code="d">2018</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000099058</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:71</subfield><subfield code="g">year:2014</subfield><subfield code="g">pages:34-57</subfield><subfield code="g">extent:24</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.addr.2013.10.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">77.00</subfield><subfield code="j">Psychologie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">71</subfield><subfield code="j">2014</subfield><subfield code="h">34-57</subfield><subfield code="g">24</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.3988676 |